Zhejiang Yatai Pharmaceutical Co., Ltd.

Antiviral drug. It has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. in vitro. After entering the cells infected by herpes virus, this product competes with deoxynucleoside for viral thymidine kinase or cell kinase, and the drug is phosphorylated into activated acyclovir triphosphate, and then inhibits viral replication in two ways: ① Interfering with viral DNA polymerase and inhibiting viral replication; ② Under the action of DNA polymerase, it binds to the growing DNA chain, causing the extension of the DNA chain to be interrupted. This product has a special affinity for viruses, but has low toxicity to mammalian host cells.

This drug has a similar structure to aldosterone and is a competitive inhibitor of aldosterone. It acts on the distal convoluted tubule and collecting duct, blocking the Na+-K+ and Na+-H+ exchanges, resulting in increased excretion of Na+, C1- and water, reduced excretion of K+, Mg2+ and H+, and uncertain effects on Ca2+ and P3-. Since this drug only acts on the distal convoluted tubule and collecting duct, and has no effect on other segments of the renal tubule, its diuretic effect is weak. In addition, this drug also has effects on aldosterone target organs other than the renal tubule.

By acting on the smooth muscle of the coronary and peripheral blood vessels and the atrioventricular node, inhibiting the influx of Ca2 into the cells, it shows the effect of vasodilation and prolonging the conduction time of the atrioventricular node, thus being effective for hypertension, arrhythmia, and angina pectoris. 1. Effect on blood pressure: reduce hypertension, reduce peripheral vascular resistance and myocardial oxygen consumption, increase cardiac output, and reduce blood pressure and show sodium diuresis without reducing the blood flow to the brain, coronary arteries, and kidneys. 2. Effect on arrhythmia: prolong the conduction time, effective refractory period, and functional refractory period of the atrioventricular node, show effects on supraventricular tachyarrhythmia, and inhibit supraventricular tachyarrhythmia caused by atrial electrical stimulation. 3. Effect on myocardial ischemia: improve the balance of myocardial oxygen supply and demand (dilate the main coronary artery and side branches, increase blood flow to the ischemic part of the myocardium, and inhibit coronary artery spasm), myocardial protection (inhibit excessive influx of Ca2 into cells during myocardial ischemia, maintain cardiac function and myocardial energy metabolism, and reduce infarct focus).

Gatifloxacin is a racemic compound of 8-methoxyfluoroquinolone, which has a broad spectrum of activity against Gram-negative and Gram-positive microorganisms in vitro. Its antibacterial effect is through inhibiting bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes. It has antibacterial activity against most strains of the following microorganisms: 1 Gram-positive bacteria: Staphylococcus aureus (limited to strains sensitive to methicillin), Streptococcus pneumoniae (strains sensitive to penicillin). 2 Gram-negative bacteria: Escherichia coli, Haemophilus influenzae and parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis. 3 Other microorganisms: Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae.

This product is a non-steroidal anti-inflammatory drug. It has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action may be to inhibit the synthesis of prostaglandins (PG) by blocking the activity of cyclooxygenase.